Skip to Content

Medivir Presented Its Cathepsin K Program at the Ongoing 31st ASBMR Meeting in Denver, USA

STOCKHOLM--(BUSINESS WIRE)--Sep 16, 2009 - Regulatory News:

Medivir (STO:MVIRB) presented preclinical data on two candidate drugs (MIV-710, MIV-711) from its cathepsin K inhibitor program in a poster session during the ASBMR (American Society for Bone and Mineral Research) meeting.

The conclusions highlighted in the presentation:

The candidate drugs described are potent and highly selective inhibitors of human cat K in vitro.

The advantageous lysosomotropic properties of these compounds resulted in enhanced potency in an osteoclast cell-based assay (Fuller et al., 2009) without any loss of selectivity at the cellular level. These inhibitors when dosed to cynomolgus monkey are well-tolerated and inhibit circulating CTX-I levels (marker of bone resorption) by up to 95%.

Moreover, duration of anti-resorptive activity exceeds plasma exposure, likely due to prolonged residence time in the targeted osteoclast cells. The high potency and prolonged efficacy duration in vivo together with excellent selectivity renders these candidate drugs highly attractive for clinical development. This includes the therapy areas of osteoporosis, osteoarthritis, rheumatoid arthritis and metastatic bone disease.

The poster is available to access on our website under IR & Media/latest events/ASBMR

For more on Medivir, please see the company website:

This information was brought to you by Cision


Contact: Medivir Rein Piir, CFO & VP Investor Relations +46 8 5468 3123 or +46 708 537 292


Posted: September 2009